Nkarta, Inc.

NasdaqGS NKTX

Nkarta, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2024

Nkarta, Inc. Dividends Paid is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Dividends paid is cash paid to shareholders as a distribution of profits.

Nkarta, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
Nkarta, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00.

Key data

Date	Dividends Paid	Capital Expenditure	Other Financing Activities	Net Cash Used Provided By Financing Activities

NasdaqGS: NKTX

Nkarta, Inc.

CEO	Mr. Paul J. Hastings
IPO Date	July 10, 2020
Location	United States
Headquarters	6000 Shoreline Court
Employees	159
Sector	Healthcare
Industries Biotechnology

Description

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key trends

Past 5 years